OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

March 30, 2023

NASDAQ US Health Care Life Sciences Tools and Services earnings 58 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks, Operator, and good afternoon to everyone. Kurt Gustafson here, OmniAb's Chief Financial Officer. I appreciate all of you for being with us on OmniAb's conference call covering fourth quarter 2022 financial results. I want to let our audience know that slides have been prepared to go along with what we say today. You can find those slides within the investors section on our site, omniab.com. Prior to starting, please be aware that remarks given on this call will contain forward-looking statements as defined under the Federal Securities Laws; such forward-looking statements carry risks and uncertainties that might lead actual results to differ materially from any results anticipated. The cautionary statements in today's press release and our SEC filings qualify these forward-looking statements. It's important to note that this conference call includes time sensitive information that is accurate only as of the date of this live broadcast, today March 30, 2023. Unless the law requires otherwise, OmniAb assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this call. With me on the call today is Matt Foehr, President and CEO. On today's call, Matt and I will cover highlights on the company's operations, partner and technology updates, and our recent financial results. Once the prepared remarks conclude, we'll open the call to questions. So with that, let me hand things over to Matt. Matt?

Matt Foehr

executive
#2

Thank you, Kurt. Hello, everyone, and I appreciate you being here for our inaugural earnings and business update call. Starting back in 2016, OmniAb has expanded and transformed via a series of strategic purchases as well as internal R&D spending efforts, growing into a frontrunner within integrated antibody discovery. Last November, we finished spinning off from Ligand Pharmaceuticals, which made OmniAb a standalone company whose shares trade publicly. Now that this deal has closed, I have strong confidence that our present corporate setup, together with our operational priorities and extensive specialized knowledge, leaves us ready to seize the growth possibilities in front of us, and by doing so, deliver a lasting effect on human health around the world. That goal of improving human health motivates our workforce of slightly more than 100 people and sets us up nicely going forward. OmniAb's extremely scalable approach — granting licenses for our discovery platform across the globe — lets our collaborators quickly create novel treatments. Our partners appreciate how we keep advancing the boundaries of enabling technologies. We think we hold the sector's sole antibody discovery platform built on four species, which makes OmniAb the broadest host system available for discovering fully human as well as bi-specific antibodies. Thanks to our demonstrated platform technology, the count of partners able to access OmniAb antibodies has risen dramatically, reaching 69 in total, with 291 active programs that now encompass three approved products. I'll share more specifics about our performance metrics on the upcoming slide. Yet something else I want to highlight is that we operate within a sizable and expanding market, where worldwide revenue from antibody pharmaceutical products is expected to hit roughly $279 billion by 2025, climbing from around $180 billion in prior years. A number of today's top-selling medications are antibody-based treatments. These represent only a few of the elements fueling industry appetite for state-of-the-art discovery technology. Our technology platform keeps demonstrating its worth to partners. Our teams achieved major progress in expanding our portfolio by bringing in 13 fresh partnerships during 2022, which included a growth deal with a partner already on board; we brought on more new partners in 2022 than at any point previously in this technology's history, something we believe sets the business up for growth ahead. As I noted, our partners are currently developing or selling 291 programs. We booked royalty revenue from the first commercial sales of both Zimberelimab and sugemalimab within China. It's likewise worth pointing out that the figures shown in the charts on these slides account for attrition. New clinical programs keep emerging from our platform. And at this point we have antibodies derived from rats, mice, and chickens that have moved into human clinical trials. As the year wrapped up, our platform had produced 28 cumulative clinical or approved antibodies, among them three additional programs that began clinical work in the latter half of 2022. Every one of these programs involves a distinct modality, offering further proof of our technology's adaptability. Three fresh initiatives make up this group: an antibody drug conjugate from Merck targeting anti-CEACAM5 for advanced solid tumors; a hexabody anti-CD27 from Genmab and BioNTech aimed at malignant solid tumors; and a trispecific antibody from Janssen for relapsed or refractory multiple myeloma. Two programs exited clinical development during 2022, since a pair of our partners shifted the therapeutic area focus of their pipelines; even so, the rate of clinical attrition for OmniAb antibodies stays quite low. Our partners currently have over 140 distinct clinical trials either ongoing or finished. Clinical trials evaluating antibodies derived from OmniAb are set to enroll, or already have enrolled, upwards of 27,000 subjects. This illustrates the substantial investments our partners are directing toward downstream development of antibodies found through our technologies. From our conversations with partners, we anticipate roughly three to five novel OmniAb-derived antibodies potentially entering clinical development during 2023, with programs targeting significant unmet medical needs; on Slide 7, our 291 programs are broken out according to development stage. A sizable and expanding base sits at the discovery stage, totaling 251 programs, alongside 14 programs now in preclinical. Within the clinic, our partners' programs total 19 in Phase 1, two in Phase 2 and two in Phase 3; and as I noted, three approved products stem from OmniAb technologies. Our view is that producing large, varied repertoires of high quality antibodies raises the odds of successfully discovering an antibody possessing optimal therapeutic characteristics. Several partners rely on multiple engineered animals from our lineup, and sometimes they'll turn to more than one of our sources for the same program. No other source species has expanded as quickly as OmniChicken, since its antibodies attach with strong affinity to a wide range of epitopes on human targets and simultaneously provide strong development profiles. OmniFlic and OmniClic are engineered rats and chickens with fixed and common light chains, designed to enable efficient bispecific antibody discovery — a field drawing growing attention from the pharmaceutical industry. Meanwhile, OmniTaur provides antibodies featuring distinctive structural properties suited to difficult targets. I should point out that OmniRat appears on this slide as the category contributing the most, and it's also the one our partners have had access to for the longest time, since it came to market before the others. Our partners tell us they really appreciate how we can offer them the flexibility to keep up with their science as it changes. On top of that, as Slide 9 shows, our technology stack supports work across several therapeutic formats and modalities. Because we can produce broad, varied sets of high quality antibodies, we think the biological intelligence built into our technologies raises the odds that therapeutic antibody discovery will succeed, while also helping to reduce how many antibody product candidates drop out along the way. Collaborators keep pushing their programs forward in development, and several shared news publicly regarding their advances in Q4 and since the start of this year. In particular, milestone payments totaling $35 million came in from Janssen, our partner, tied to TECVAYLI, which Kurt will cover in greater detail shortly. Turning now to batoclimab: Harbour BioMed recently released positive top-line results from a Phase 3 trial testing it as a therapy for generalized Myasthenia Gravis. Beyond that, Immunovant said a Phase 3 study of batoclimab is now underway in thyroid eye disease, as well as a pivotal Phase 2b trial in chronic inflammatory demyelinating polyneuropathy. Now turning to Zimberelimab: favorable results emerged from the ARC-7 Phase 2 trial's fourth interim analysis, according to Gilead and Arcus Biosciences. That study examined first-line treatment in metastatic non-small cell lung cancer patients. On the sugemalimab front, EQRx reported that UK and European regulators have accepted marketing authorization submissions for first-line therapy in metastatic non-small cell lung cancer. CStone also shared further updates from China. Our engineered transgenic animals' biological intelligence drives our technology stack, and when paired with our high throughput screening technologies, it enables discovery of high-quality fully human antibody therapeutic candidates spanning a broad spectrum of diseases. As I noted earlier, we think we hold the industry's sole four species in-vivo antibody discovery platform, which makes OmniAb's host repertoires the most varied out there. The experience we have, together with ongoing conversations we have with our partners, provides us with essential insight into the industry, and this generates a positive feedback loop that lets us advance and innovate around our proprietary platforms.

Matt Foehr

executive
#3

We've got a collection of in-silico instruments for therapeutic discovery along with optimization, and those are integrated across our different technologies and capabilities. Structural modeling is among these tools, as are large multi-species antibody databases, artificial intelligence, plus machine learning sequence models, and others besides. What these capabilities do is boost our capacity to quickly pinpoint candidates possessing the correct affinity, specificity and developability profiles, which results in drug development that's more effective and efficient for our partners. Beyond that, we possess substantial capabilities focused on ion channels and transporters, which were founded and constructed around small molecules and hold obvious promise across numerous formats and modalities. Moreover, we believe we're able to open up possibilities for entirely novel paradigms when it comes to targeting ion channels and transporters. We keep putting money into innovating our technology, even as we assess strategic technology acquisitions and licensing opportunities so we can broaden our capabilities even more; take February, for instance, when we signed a license agreement with mAbsolve covering its Fc Silencing Platform technology. Through that agreement we obtained exclusive sub-licensable access to the STR technology, which is going to give our partners the capacity to silence effector functions efficiently, assisting them in discovering and developing therapeutics that are safe and effective. That marks the most recent illustration of creatively expanding our platform. We're likewise eager to introduce fresh innovations tied to our platform during this year, and our rollouts of new technologies will by and large line up with the major antibody engineering and antibody discovery conferences taking place this year. As I noted earlier, we feel we're positioned well for growth going forward, since we capitalize on our extremely scalable business model and assist our partners' pipelines as those grow and move toward the clinic. Via our business development work, our intention is to bring additional license agreements and additional partners into our portfolio. On top of that, we stay dedicated to putting resources into our proprietary technology platform so as to strengthen our standing as a marketplace leader and to keep giving our partners workflow versatility. To offer just a single illustration, in the fourth quarter of this year we intend to introduce a heavy chain-only transgenic chicken, something we regard as a significant new innovation that our partners are going to want access to. We're eager to keep you informed about these developments as the year goes on. Having said that, I'll hand the call back to Kurt so he can discuss the financials. Kurt?

Kurt Gustafson

executive
#4

Appreciate that, Matt. Before we get into the numbers, I want to take a couple of minutes to walk through how our business model works and the way our licensing deals are set up with partners. A central feature of how we structure these deals is that they're meant to bring the economic and scientific goals of both sides into alignment. What that means is we've built the deals so that payments come to us when our partners succeed. We aim to keep the cost of accessing the technology fairly low so partners feel encouraged to use it as much as they'd like; regarding how these agreements are put together, they usually start with an upfront payment that grants access to the full technology stack. On top of that, there's the possibility of earning collaboration or service revenue if a partner requests work from us. Beyond that come milestone payments tied to progress of programs in the clinic and to regulatory approval; and finally, royalties on net sales of partner products. Our view is that revenue growth over the long term will mainly come from royalties. That said, my expectation is that milestone payments will account for most growth over the next few years. Now on to the financial results — keep in mind that OmniAb sat inside Ligand during the first 10 months of the year. That means results before November 1 were put together on a carve-out basis. Beginning with revenue, Q4 2022 total revenue came to $35.3 million, versus $15.3 million in the same quarter a year earlier. The main driver of that increase was recognition of the U.S. based Teclistamab milestone of $25 million during the quarter. For the first commercial sale in Europe, we expect the remaining $10 million of milestone revenue to be recognized later in 2023. Recognition of this milestone as revenue comes with specific accounting criteria. As of today, our belief is that those criteria haven't been satisfied. So it's likely this $10 million won't be recognized even in Q1, but probably later in the year. Our service revenue declined a bit because less work was done for certain ion channel partners, in part because some of those programs succeeded and moved to the next stage of development. Operating expenses in Q4 totaled $26.3 million, against $20.4 million in 2021. That increase reflected costs required to support our standalone structure as an independent public company. It covers higher staff costs from hiring in various G&A functions, along with other typical public company costs; however, I'd point out that this quarter also carried roughly $2 million of expenses that were more onetime in nature. Net income for the quarter was $6.8 million, or $0.07 per diluted share, compared with a net loss of $3.1 million, or a loss of $0.04 per share, in the year ago period. When you look at the whole of 2022, our total revenue came to $59.1 million. What drove that revenue higher was mainly the additional milestone revenue that I mentioned earlier, plus royalty revenue generated by our partners' sales of Zimberelimab and sugemalimab. Operating expenses for 2022 came in at roughly $85.7 million, up from $70.4 million in 2021. The same factors that pushed up the fourth quarter were largely behind that increase, and they mostly have to do with expanding our R&D infrastructure, along with OmniAb getting ready to operate as a standalone company. For the full year, net loss was $22.3 million, or $0.26 per share, compared with a net loss of $27 million, or $0.33 per share, in 2021. I'd also like to say a couple of things regarding taxes. At the start of 2022, a new federal tax law took effect that altered how R&D expenses get deducted. Under this new law, U.S. R&D expenses generally must be amortized and expensed across a five year period. Because of that tax law change, together with the recognition of the Teclistamab milestone, we will be a cash taxpayer for the fourth quarter sub period during which we were an independent company. And for the full year of 2023, we expect to be a cash taxpayer as well. Ultimately, this is really only a timing difference when it comes to taxes, since we will eventually realize the full benefits of all our R&D costs. Let me also add a few remarks about the share count for EPS. The share count numbers we used for EPS, both for the full year and for Q4, represent a blended share count covering the period before the spin out, which was approximately 82.6 million shares, and the shares outstanding after the spin out, which was approximately 98.9 million. Looking ahead, the 98.9 million basic shares outstanding will be the more suitable base figure to use when calculating EPS. As a quick reminder of the various pieces of our capital structure, beyond the public float shares, we have roughly 16 million earn-out shares outstanding, plus various employee equity awards and warrants. The earn-out shares expire five years after the spin out transaction closes, and half of them vest at a price of $12.50, while the other half vest at a price of $15. The warrants likewise have a five year life and a strike price of $11.50. On the face of our financial statements, you'll see that we have 115 million shares issued and outstanding. That reflects the combination of the basic share count and the earn-out shares. We closed the year with $88.3 million in cash, cash equivalents and short term investments. As we previously disclosed in January, we received $35 million in milestone payments from Janssen tied to the launch of Teclistamab. With these milestone payments added in, we are in a strong capital position. On an operating basis, cash flow has been hovering around the breakeven point for the past 2 years or so. That leads us to believe the cash we currently hold provides enough runway to support operations for the foreseeable future. When it comes to specific guidance, we anticipate that our cash balance at the close of 2023 will come in a bit above where it stood on 12/31/22. I'll wrap up my remarks by walking through our financial outlook for 2023. To give some perspective, I thought it would be useful to begin by examining our operating expenses across the 4 quarters of 2020; the fourth quarter, then, was the first one in which OmniAb reported as a standalone public company. Because of that, Q4 offers the best representative baseline for our operating expenses going forward. As Matt said, we'll keep investing in R&D, so I'd anticipate our quarterly R&D costs in 2023 rising from this Q4, 2022 base. Turning to G&A, keep in mind that this line contained close to $2 million of expenses that were non-recurring in nature. If you strip out those onetime expenses, our G&A expense level for Q4 is largely consistent with what we expect in subsequent quarters across 2023, with some nominal growth. One last thing — I'm happy to share that we've brought on a new Head of Investor Relations. She's Neha Singh, and I'm looking forward to introducing her to all of you over the coming weeks. With that, I'd like to open the call for questions. Operator?

Nishant Gandhi

analyst
#5

Hello, I'm Nishant, filling in for Robyn. Great work on everything you've achieved, and I appreciate you fielding my questions. First, regarding royalties — I realize you closed many additional agreements with important partners during the past year, and your platform has now been validated through over 25 programs in clinic. So looking ahead at programs, would you anticipate seeking higher royalty rates on any of them, given all the validation your projects have received? Then on the topic of pipeline variety, I notice that among the programs in clinic, you have considerably more molecules in oncology. Does that factor into your plans moving forward — to branch into additional disease areas and secure fresh partnerships there? Thanks.

Kurt Gustafson

executive
#6

Yeah, perhaps I'll handle the first portion of that, and Matt, you can address the second portion. When it comes to royalties, you're completely correct to highlight that as the platform has gained greater validation, we've in fact managed to secure improved economics on certain deals. So I cannot forecast how that will look in the future; however, if I examine the past, and look at the typical royalty rate for agreements signed in each of the previous five years, a modest upward trend appears in terms of greater royalty rates across those agreements being signed; and I believe that simply reflects, as you mention, the technology's validation causing it. So we're hopeful that this persists, though it's hard to predict in the future. But Matt, on the diversity question.

Matt Foehr

executive
#7

Yes, thank you, Nishant, for raising that. You're right to note that when you consider the programs that entered the clinic first, our platform has now produced 28 clinical programs in total, cumulatively. So from that standpoint, it's strongly validated. That said, you're right — the bulk of them, from a therapeutic area standpoint, sit in oncology, though a few are in GI-disease, in immunology, and some also in inflammation. But if you look at the pie chart on Slide 7 of the deck, the split there shows that as you move further down the pipeline, particularly in preclinical and discovery, we're starting to see the platform applied across therapeutic areas, which is what you'd expect — areas like CNS diseases, inflammation, women's health, infectious diseases and others. So I believe that over time, as those programs advance and move through development, we'll see that diversity grow in the clinic.

Nishant Gandhi

analyst
#8

Thank you, that's great.

Analyst

analyst
#9

Hi, appreciate you taking my question. Josh here, filling in for Steve. To kick things off, I'd like to know which one of your transgenic animal platforms has drawn the greatest level of interest. Also, how do you expect the further development and prioritization of those platforms to evolve over the next several years? I've got a few more questions after that.

Matt Foehr

executive
#10

Thanks, Josh, appreciate the question. Yes, this time around we provided some data to give a bit of a breakdown regarding how the source technology — the antibody source technology — that our partners are using is distributed. When you take a look at everything we have in our portfolio, slightly over 50% of the programs our partners are actively advancing through development make use of the OmniRat platform. OmniRat holds the distinction of being the very first platform we brought to market — it was our initial launch — and it remains a transgenic rat in widespread use. In the mouse arena, sure, those animals exist, but what makes the rat stand apart is its uniqueness. Over time, it has demonstrated the ability to generate strong antibody responses for our partners. On top of that, OmniRat offers considerable efficiency and flexibility to our partners, which lets us plug into their workflows in an adaptable way. For certain partners who are launching many programs each year, we've gone as far as establishing OmniRat breeding colonies—so clearly, OmniRat represents a substantial resource. When it comes to which offering is expanding quickest by percentage, OmniChicken is the one I'd highlight. Its evolutionary distance is the main reason the chicken brings benefits. Relative to humans, mice, and rats, chickens sit very far apart on the evolutionary tree, which opens up numerous advantages that our partners are eager to capitalize on. Since OmniChicken was acquired and folded into the OmniAb platform technology, we've managed to grow the count of partners using it by roughly tenfold. Beyond that, we're witnessing strong growth in the bispecific space as well, driven by OmniFlic — a transgenic rat that has a fixed light chain — along with OmniClic, a transgenic chicken possessing a common light chain. As a matter of fact, when you look at the more advanced clinical programs that our partners are advancing, a large number of them are bispecific antibodies. That's an area partners are caring about more and more. I'd also bring up OmniTaur on top of that. Although the programs running at present account for only a modest portion, this field garners significant attention and a great deal of incoming inquiries, because our business development team is currently in talks with potential new collaborators. The reason is that structural traits inspired by bovine antibodies could unlock fresh paths for treatments built on antibodies—something numerous partners report having previously found out of reach. That has us enthusiastic too.

Analyst

analyst
#11

Great, that leads well into my next question about the way you usually decide how to rank collaborations involving smaller biotech firms versus big pharma. Are you noticing a significant gap there? Also, are you seeing generally reduced BD activity among smaller cap companies because of broader tightening in macro R&D budgets?

Matt Foehr

executive
#12

Sure, I'll offer a few thoughts, and Kurt might want to chime in with additional ones too. We've just come off a year — the prior year — in which we formed more new partnerships than at any other point in the technology's history, correct; and a big share of those partnerships come from what I'd call inbound interest or scientist migration, scientists who had good experiences at one licensed partner, then relocated to a new company and now seek access. So we find that both interesting and significant, since I believe it also highlights the opportunity, which explains why we have been and continue to grow our business development team, essentially to handle that rise in inbound interest in obtaining access to cutting edge technologies as the industry has moved increasingly toward antibody-based medicines. Several of the partners we've brought on have been funded biotechs, earlier in their lifecycle, yet many of them possess a great deal of really compelling biology. Clearly we already hold existing partnerships with quite a few big pharmas. And they use our platform heavily. And at any given moment we are continuously talking with numerous parties across various stages of development, always working to negotiate new license deals or terms. And those involve large pharma players too, who I think recognize, particularly now following — with our new structure, our dedication to ongoing innovation and our dedication to staying at the forefront of antibody discovery. Those sorts of things draw in not just biotechs with interesting biology, but the large pharma players as well. Kurt, I'm not sure, if you'd like to add anything on that or anything else.

Kurt Gustafson

executive
#13

The one point I'd probably make is that, generally speaking, prioritizing these items isn't something we truly have to do, correct? That kind of choice would likely be necessary only if capacity were a constraint. Yet capacity isn't really a constraint for us. Take work involving OmniRat, for instance: in the majority of those cases, our partners receive shipments of the rats from us, and they handle everything; as a result, that model can scale essentially without limit on our end. So choosing one deal above another isn't genuinely required. What this comes down to is getting as many parties as possible to sign on, and pushing them to adopt the technology to the greatest extent we can.

Analyst

analyst
#14

Great. And finally, on that new asset specific to J&J, would you characterize it as royalty bearing? Or will the deal structures be similar, as with Teclistamab?

Matt Foehr

executive
#15

Yeah, that J&J deal was signed very soon after OmniRat's launch. And in fact, it was a deal inked by a predecessor company we acquired, O&E. The structure of that deal provides for a payment in the U.S. upon commercial launch; and then a payment in Europe. So compared with the Teclistamab deal, it's simpler, right? So for those markets, that asset carries $35 million in payments.

Analyst

analyst
#16

Great. Thanks for taking the question.

Joe Pantginis

analyst
#17

Hey, guys, good afternoon. It must feel good to have that first standalone earnings call behind you; so my opening question concerns the BD work you're doing underneath everything. So — and your business model; so first, clearly, the figures you've got, the count of partners and the count of programs in development, basically function as a built-in marketing engine. So I suppose, how would you characterize what you're doing in 2023 right now when it comes to push versus pull, meaning, what portion of your existing BD arrives through inbounds versus the amount of marketing you've needed to undertake?

Matt Foehr

executive
#18

Yeah, thanks, Joe. Regarding your comment that it works as a built-in marketing engine, that's absolutely right. I believe we've gained over time from partners discussing, at podiums at antibody engineering or protein engineering conferences, the success they've enjoyed with our platform. And that occurs, reliably. We notice it. One instance that comes to mind is Amgen lately featuring how well OmniFlic worked for them at an antibody conference just very recently. And a great deal of inbound interest gets generated by that. And most of the deals we've closed have originated from that kind of situation where partners describe how well the platform worked for them, and that leads others to grasp it. Beyond that, the degree of clinical validation, I believe, matters too; and today, given how many clinical programs our platform has yielded, greater visibility is created for others working in antibody discovery. Something we've been concentrating on, and have done more of lately, is genuinely broadening our business development reach, first to seize that opportunity. This year we're in fact stepping up how often we attend conferences tied to business development, tied to licensing, and related ones; we're working alongside some of our partners on joint presentations, and publications. And we believe each of those moves leaves us ready to genuinely seize the opportunity that has been created by the innovation, and the ongoing innovation, that we're dedicated to from here on; so as I mentioned, at any given moment we're continually working through new license deals, new partnerships, and we're enthusiastic about where we stand today and how our team is handling it.

Joe Pantginis

analyst
#19

That's a big help, Matt. Appreciate it. Now, on the subject of your core business — you mentioned this during your prepared remarks — you noted, for instance, that OmniChicken was growing the quickest, and with new tech, you're always at work on it. You're also aiming to present at things like antibody engineering conferences. So perhaps, without revealing the secret formula at this moment, what sorts of broad technological enhancements are you considering, and which you'll be in a position to tell the street about.

Matt Foehr

executive
#20

Yeah, thank you, Joe. Like I mentioned, we intend to roll out new developments tied to our technology at big antibody engineering or protein engineering conferences throughout the year. There are pieces — from our standpoint it's an ongoing, endless effort when it comes to keeping the platform innovative; we hold a genuinely distinctive, and I'd say significant, position in the industry, with 69 partners, and a number of active programs through which we truly get to have that deep, collaborative conversation with partners to grasp not just their present needs, but additionally to anticipate the technological direction they're moving in. Once you begin hearing identical feedback from several large pharma companies and smaller biotechs, you genuinely develop a solid feel for which innovations will be broadly applicable throughout the industry. A case in point that's genuinely behind us was where we stood a few years back when we launched OmniFlic and OmniClic, really spotting the bispecific space taking shape many years ago. And that's among the reasons we began engineering heavy chain only chicken a couple of years ago. That was carried out together with one of our large pharma partners. But it's going to be made available, and we intend to introduce it during the fourth quarter of this year. Heavy chain only antibodies possessing plenty of intriguing and attractive traits. We've transformed them into antibodies or pica <<inaudible>> bodies in certain cases, but they're able to unlock novel therapeutic strategies and carry other biological advantages that we believe will be something our partners want. So that's one we anticipate launching at a major conference in the fourth quarter.

Joe Pantginis

analyst
#21

Great, thanks for the color guys.

Matt Foehr

executive
#22

Thanks Joe.

Steven Mah

analyst
#23

Okay, thank you for taking the questions. Regarding your active partners, I've got a question with two parts. Assuming my calculations are correct, it appears that 13 new partner ads came in while 12 rolled off during the quarter. So my question is, among those 12 programs that rolled off, had any been paused, or were they simply terminated? Or is there a chance they might come back? Then for the second part, can you tell us a bit about those 12 partners that rolled off? Would you say they're predominantly big pharma, large biotechs, or small biotechs? Thanks.

Matt Foehr

executive
#24

Yeah, thank you Steve. I'm not — I don't believe I'm tracking with your math. One thing I'd like to mention, we brought on 12 new partners during the last year, all through the year. And one of — and after that we signed an agreement that expanded things with a partner we already had. So we might — there could be some confusion, or perhaps what we're discussing is — you're referring to quarter versus annual; we didn't have any partners rolling off; so perhaps that needs clarifying, or maybe programs and partners are being interchanged.

Steven Mah

analyst
#25

No, my calculation was off. Yeah, apologies — I was reviewing — my mistake. This is the first time I've joined one of your calls; but yes, I had been comparing an annual figure against a quarterly one. All right, yes, understood. I see it now.

Matt Foehr

executive
#26

Great.

Steven Mah

analyst
#27

Then regarding those 13 partner additions, might you provide some detail about the kind of partner and whether they're pharma or biotech, and you mentioned OmniChicken is expanding most rapidly. Might you tell us what share of these newly added partners came in for OmniChicken?

Matt Foehr

executive
#28

Yes, I believe I can offer a bit of detail on that. Out of the 12 new partners brought on during the last year, most were biotechs, and these are businesses with — well-capitalized businesses that are advancing a program; our bar is high for what we treat as an active partner and an active program. And we possess some truly intriguing biology that I believe energizes our scientists and carries the impact and potential for impacts on health in intriguing ways; so that's a space our team keeps being enthusiastic about. As for how many are utilizing our different technologies, it's genuinely a blend, correct, in terms of what draws partners to our platform. One is the versatility to employ on the chicken, say for a program where that's a perfect fit. Yet simultaneously certain of those new partners might also be employing OmniRat or OmniFlic too. So it genuinely is a blend and partners do appreciate the fact that they receive access to multiple technologies when they take a license with us. And we can genuinely hold a deeply scientific dialogue and match the technologies to their needs, not just from a scientific standpoint, but also from an operational standpoint regarding what suits them best.

Steven Mah

analyst
#29

All right, that's great. And if I could slip in one final question here — regarding this deal with mAbsolve, can you help us understand how the structure works? Is it structured as a joint venture? Or does it function purely as a licensing fee arrangement? And do they qualify to get milestones or royalties from your side?

Matt Foehr

executive
#30

Sure, I'll begin by giving you a bit more detail on that. Actually, let me first address the economics side of it. mAbsolve doesn't receive any downstream economics. This is a licensing arrangement in which we can exclusively license their STR FC Silencing technology to our partners with antibodies generated using the OmniAb platform. And mAbsolve has no downstream participation. Now, pulling back a bit to add some additional context — clearly, FC-mediated immune effector activities matter, as they're genuinely a significant component of how an antibody naturally functions. However, with many therapeutic antibodies, those interactions aren't wanted or may result in adverse effects. And clearly, many different methods exist for eliminating effector function. Yet those come with numerous limitations. So the STR Fc Silencing Platform that mAbsolve created impressed us. It was recently detailed in a PLoS ONE paper, and from our perspective it provides the most truly silent FC mutations described to-date. As a result, it could enhance safety and efficacy for therapeutic antibodies and FC fusion proteins. And now it's something we're able to offer to our partners downstream. So I hope that provides a bit more color.

Steven Mah

analyst
#31

Yeah, that helps. Thanks; and sorry about the confusion regarding the new partners.

Matt Foehr

executive
#32

It's totally fine.

Kurt Gustafson

executive
#33

Thank you, Steve.

Puneet Souda

analyst
#34

Hi, everyone. I appreciate you both, Matt and Kurt, for fielding my questions. To start, perhaps I could pose something at a broad level regarding the funding environment for smaller biotech firms, which clearly stands out as a significant concern right now. That's something we're observing among the businesses supplying tools and services to those smaller biotech players. Could you perhaps share what you're observing from where you sit? How does that factor into the guidance you've set for the year? And if possible, I'd like to hear about the programs for the entire year. I recall you mentioned ion channel partners came in a bit lower. Yet you also noted clinical attrition is still quite minimal, which strikes me as a good sign, but I was hoping you could help us understand the situation among the smaller biotech companies. Is that something you're factoring into your full-year guidance?

Matt Foehr

executive
#35

Yes, Puneet. Thank you. Matt here, and Kurt will likely chime in as well. Clearly, we're monitoring the sector and grasping the worldwide situation. We're exiting a stretch during which substantial capital flowed into biotech firms, correct. So — and I'm referring somewhat to what's behind us; what we've discovered through conversations with our partners is that this has produced a genuine emphasis on investment, I mean, once more, following a year where last year brought the highest number of new partnerships we've ever had. And there appears to be a lasting dedication to discovery, correct. On a broad scale, I believe discovery is clearly vital, and regarding expenses with partners, we haven't observed the kind of impacts you seem to be suggesting, judging by our discussions with them. When you attend the conferences where we're present, the sole topic everyone wants to discuss is fresh approaches to antibody-based targets, structural components that perhaps only our scientists can clarify or grant access to. There's genuinely a strong emphasis on staying at the forefront of innovation during that discovery stage. So naturally we'll keep monitoring the sector and so on; however, we're coming off a year in which we brought on more new partners than at any point before. That demonstrates new partners' dedication to gaining access to the technology in order, in many cases, to accelerate projects rapidly; but ideally, that provides you with some additional insight. Kurt, is there anything else you'd like to include?

Kurt Gustafson

executive
#36

I mean, I think you're correct there. I mean, if someone had said to me back in 2021 that during 2022 we'd ink a greater number of agreements than at any point before, I probably would have pushed back on that, simply because of how things look with financing across biotech. Still, it's obvious that interest remains.

Puneet Souda

analyst
#37

Understood, that's excellent and heartening considering the environment we're witnessing right now. Another thing, perhaps directed at Kurt, regarding the cash situation and the position you hold, and considering the capabilities you presently possess on the animal platform — a varied platform throughout — that's where the strength lies. Yet, looking at the broader technologies, how they measure up regarding screening, pinpointing the correct antibodies going forward, assays and such, since valuations have declined somewhat throughout the sector in certain of those technologies, and possibly even in private markets, how are you thinking about the whole thing — your technology stack and capabilities, and the investments going into it? Should we consider more in-house efforts, or organic? Or should we consider additional opportunities out there that you might pursue to enhance those capabilities?

Kurt Gustafson

executive
#38

The brief response, I'd say, is both. However, I don't believe we must pursue M&A, in the sense that truly, nothing appears to be absent from the technology stack. Having said that, we've got — our attention is fixed on particular technologies we believe would complement the technology stack we currently possess. And we are watching for those. A portion of that might arrive via acquiring technology that is outside our company at present. A portion will be certain internal investment that we intend to make; but we possess an internal strategic plan for how we wish to further build out our technology stack. And we will carry that out; and I believe it will be a mix of both internal investment along with some acquired — acquisition of new technology.

Puneet Souda

analyst
#39

Understood. Then my final question concerns the OmniChicken platform — you mentioned possible future additions involving cow-derived ultra-long CDRs. Could you give us an update on where things stand with that?

Matt Foehr

executive
#40

Yes, yes, thank you, Puneet. We didn't address it during today's prepared remarks. What we highlighted was the heavy chain only chicken launch, which is set for Q4. Still, you're correct to raise one of the reasons behind the OmniTaur platform and behind buying the company that initially housed it: it creates the chance for us to engineer those distinctive bovine-like long CDR-H3 traits into a humanized chicken host. A great deal of science supports this. Our team is making excellent progress on it, and it's something we're quite enthusiastic about. We believe we're positioned in a way no one else is — possibly the sole group worldwide capable of doing it. That program will get more discussion from us down the road. It's also the sort of innovation that draws partners in, since they see what impact it might deliver, particularly for things such as CNS diseases, or other infectious diseases, or emergency settings, or various targets where embedding that structural feature within a humanized chicken host unlocks rather considerable and meaningful possibilities further along, and it aligns especially well with what we can do involving ion channels and transporters, too, since those are targets where this technology might matter even more. Combine that with our very high throughput electrophysiology abilities, developed across a great many years — decades, in fact — and we think our screening capacity for ion channels and transporters may rank among the biggest anywhere globally. So when you bring together a capability like that with what's being engineered into OmniTaur — an OmniTaur-type chicken, broadly speaking — it could produce a rather notable effect on the industry further downstream. We expect to say more about this later on, but it's simply one more illustration of the tech expansion and advancement efforts happening internally.

Puneet Souda

analyst
#41

Understood. That's great, and congratulations on this debut quarterly earnings call — it's a strong one. Appreciate it.

Kurt Gustafson

executive
#42

Thanks.

Matt Foehr

executive
#43

Thanks, Puneet.

Yuan Zhi

analyst
#44

Appreciate you taking our questions. I've got a couple for you. Matt, a number of companies in your space are turning to AI for antibody generation. When you're speaking with prospective clients, I'm curious whether that subject comes up in conversation. And which aspects of your platform do you believe will convince those customers that yours is the correct option?

Matt Foehr

executive
#45

Yeah, thank you; I'll offer a few thoughts. Honestly, what sits at the heart of our technology is something we refer to as biological intelligence. That rests on a premise that antibodies produced in vivo outperform those from other sources, mainly since they undergo natural optimization via an iterative process that favors selection of antibodies possessing outstanding specificity alongside developability profiles. That capacity of the immune system within our engineered transgenic animals is something only we have been positioned to accomplish, and it has also been refined across millions upon millions of years of evolution. So those optimized antibodies, together with our animals' capacity to produce them, is what we term biological intelligence. This method genuinely boosts efficiency along with the likelihood of success. It's what draws many partners toward us; and in our view it additionally helps reduce attrition among antibody candidates during clinical development. With that said, we clearly employ in silico tools here constantly, obviously, distributed among our three scientific locations here in Emeryville, in Tucson, Arizona, where a devoted in silico team with a lengthy track record in modeling and structural modeling, plus a wide array of additional capabilities, operates, along with our group in Durham, North Carolina. So I suspect it may be somewhat underappreciated that here across many years, we've assembled a collection of in silico tools for therapeutic antibody discovery and optimization that are genuinely interwoven with and matched to our technologies. These two tools are, as I mentioned, structural modeling, yet they're matched with extensive multi species, antibody databases; and that piece is truly essential. If you've worked through as many programs as we have across many years, deep collaborations with partners. And afterward we apply that and we also tap AI and machine learning here too. And that's another thing I believe our partners appreciate, perhaps not widely recognized that we do so because for us, it's solid science, you integrate it. But absent that biological intelligence source that was constructed over millions of years of evolution, those tools are constrained without it. We clearly tap that too; and we take pride in advancing programs for our partners, combining those internal capabilities, naturally, with our novel transgenic animals.

Yuan Zhi

analyst
#46

Yes, understood. That's a really useful and in-depth look at your platform; and Kurt, maybe this one's for you, since we want to grasp what makes your business unique. As you're aware, there are royalty deals currently active in the markets. Could you remind us of any conversations you might have had with those royalty players about monetizing your future royalty, or possible collaborations, or anything else you're thinking about? That would be really helpful.

Kurt Gustafson

executive
#47

Sure; those people reach out and we do talk with them; so we definitely know those options exist out there. In terms of where we are right now, though, as I mentioned, we have a strong capital position, correct. This business is in some respects a fairly mature one. It's fairly near breakeven cash flow; and with the amount of money on our balance sheet at present, we're basically set. Looking ahead, I don't see any need to raise more capital, unless we were to do some kind of acquisition. So we do speak with those people. We know what's available out there, but it's not really part of anything we're considering right now.

Kurt Gustafson

executive
#48

Understood. That covers everything we wanted to ask. Appreciate it.

Kurt Gustafson

executive
#49

Wonderful, thank you, Yuan.

Matt Foehr

executive
#50

Alright, thank you. I want to express my appreciation to everyone for being on today's call, and for the questions and involvement. As I wrap things up here, I also want to take a brief moment to recognize our employees, because finishing a separation from a publicly traded company is a major undertaking, and it requires business endurance, constant focus on the details, and cooperative teamwork. And we have had to handle all of that while continuing to operate and expand the business, assist our partners, and keep innovating on the technology side too. So I want to thank the employees. And I will say that as a team, we feel very good about where we stand and about our capacity to create value for every stakeholder, including, naturally, our partners, and naturally, and importantly, all of you, the investors. So we keep these matters at the forefront here at OmniAb. And so I just wanted to finish with that. I will also note that we will be participating in a few investor conferences soon; we will be at the H. C. Wainwright BioConnect Conference at the NASDAQ headquarters in New York City on May 2, and we also intend to be at the EF Hutton Global Conference on May 11, which is in New York City as well. So we look forward to continuing to update you on our progress, and I hope everyone has a wonderful day. Thank you.

Operator

operator
#51

Thanks. That brings today's conference to a close. Appreciate everyone for joining in. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.